Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.04
$0.28(6.93%)
At close: 4:00 PM EDT
$4.04
$0.28(6.93%)
Day’s Range― - ―
52-Week Range$3.00 - $16.16
Previous Close$4.32
Volume70.14K
Average Volume (3M)259.55K
Market Cap
$78.67M
Enterprise Value$37.69
Total Cash (Recent Filing)$147.19M
Total Debt (Recent Filing)$104.45M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Nov 10, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding18,797,165
10 Day Avg. Volume125,119
30 Day Avg. Volume259,552
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.67Price Target Upside89.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$125.73M
Bulls Say, Bears Say
Bulls Say
Multi-year HCA ContractThe HCA agreement provides contracted console demand and multi-year revenue visibility while reinforcing Tablo’s position within a major hospital network. It may also support broader adoption of Outset’s in-sourced dialysis model across additional facilities.
Improving Gross MarginsGross-margin expansion from product-cost improvements, lower overhead and service efficiencies indicates improving unit economics. Management’s stated path toward a 50% company-wide margin could strengthen operating leverage as the installed base and treatment volume expand.
Reduced Leverage And LiquidityThe sharp reduction in debt from prior years materially improves financial flexibility, while substantial liquidity supports continued product development, implementations and commercial execution. This buffer gives management more time to pursue profitability without immediate balance-sheet strain.
Bears Say
Persistent Operating LossesDespite better margins and narrower losses, Outset remains materially unprofitable and spends ahead of its current scale. Sustained losses leave execution sensitive to growth and adoption rates, delaying the point at which the installed base can produce durable earnings.
Negative Cash GenerationThe company continues consuming substantial cash to fund operations, even though the burn rate has improved from 2024. If profitability does not advance as planned, ongoing investment needs could reduce liquidity or require external financing, limiting strategic flexibility.
Recurring Revenue SoftnessConsumables and service revenue are central to Tablo’s recurring, utilization-driven model. Their recent contraction suggests that installed-base monetization is not yet consistently scaling, and prolonged weakness could restrain revenue quality, margin leverage and the path to breakeven.
Outset Medical News
OM FAQ
What was Outset Medical, Inc.’s price range in the past 12 months?
Outset Medical, Inc. lowest stock price was $3.00 and its highest was $16.16 in the past 12 months.
What is Outset Medical, Inc.’s market cap?
Outset Medical, Inc.’s market cap is $78.67M.
When is Outset Medical, Inc.’s upcoming earnings report date?
Outset Medical, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 76 days.
How were Outset Medical, Inc.’s earnings last quarter?
Outset Medical, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.083.
Is Outset Medical, Inc. overvalued?
According to Wall Street analysts Outset Medical, Inc.’s price is currently Undervalued.
Does Outset Medical, Inc. pay dividends?
Outset Medical, Inc. does not currently pay dividends.
What is Outset Medical, Inc.’s EPS estimate?
Outset Medical, Inc.’s EPS estimate is -0.69.
How many shares outstanding does Outset Medical, Inc. have?
Outset Medical, Inc. has 18,797,165 shares outstanding.
What happened to Outset Medical, Inc.’s price movement after its last earnings report?
Outset Medical, Inc. reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of Outset Medical, Inc.?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (89.77% Upside)
$7.67 (89.77% Upside)
Blogger Sentiment
Bullish
OM Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 236.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.07%
Trailing 12-Months
Company Description
Outset Medical, Inc.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrays a predominantly positive commercial and operational trajectory: modest year-over-year revenue growth with strong sequential momentum, meaningful gross margin expansion, a significant $40M refresh agreement with HCA that establishes backlog, a strengthened balance sheet with controlled cash burn, notable implementation and customer success achievements, and an encouraging pilot for next-gen Tablo expected to drive future refresh cycles. Offsetting this optimism are near-term softness in consumables (down 12%), a small decline in product and recurring revenue, continued non-GAAP operating losses, and inherent capital-sales timing variability. On balance, the company communicated improving fundamentals and clear strategic catalysts that outweigh current headwinds.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(89.77% Upside)
Technical Analysis
Ownership Overview
18.94% Insiders
21.11% Mutual Funds
27.24% Other Institutional Investors
27.54% Public Companies and
Individual Investors